To evaluate the therapeutic efficacy of panobinostat in ATRT, we cultured a panel of human SMARCB1-deficient ATRT cell lines (BT12, BT16, CHLA04, CHLA05, CHLA06 and CHLA266) belonging to the ATRT-SHH and ATRT-MYC molecular subgroups and a neural stem cell (NSC) control cell line with intact SMARCB1 (Figure 1a, Supplementary Figure S7) in increasing concentrations of panobinostat. This evidence concerns the gene SHH and atypical teratoid rhabdoid tumor.